Compared with other groups, Group B exhibited a more significant increase in MMAS-8 scores (all p < 0.05).<h4>Conclusions</h4>Metabolic phenotype exerts substantial effects on the therapeutic outcome of sertraline in patients with depression carrying the CYP2C19 gene. The gene discussed is CYP2C19; the disease is depressive symptom measurement.